Y.D. More Investments Ltd Has $2.97 Million Stock Holdings in OPKO Health, Inc. (NASDAQ:OPK)

Key Points

• Y.D. More Investments Ltd increased its stake in OPKO Health, acquiring an additional 377,179 shares, bringing its total ownership to approximately 1,772,947 shares, valued at around $2.97 million.
• OPKO Health reported a negative earnings per share (EPS) of ($0.19) for the quarter, falling short of analysts' expectations and marking a 13.9% decline in revenue year-over-year.
• Institutional investors collectively control 64.63% of OPKO Health's stock, reflecting strong interest from major financial entities in the biotechnology company.

Y.D. More Investments Ltd raised its holdings in shares of OPKO Health, Inc. (NASDAQ:OPK - Free Report) by 27.0% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,772,947 shares of the biotechnology company's stock after buying an additional 377,179 shares during the quarter. Y.D. More Investments Ltd owned about 0.22% of OPKO Health worth $2,971,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in OPKO Health by 1.0% in the first quarter. Vanguard Group Inc. now owns 29,500,071 shares of the biotechnology company's stock valued at $48,970,000 after acquiring an additional 293,740 shares during the period. Millennium Management LLC boosted its stake in OPKO Health by 85.3% during the fourth quarter. Millennium Management LLC now owns 4,588,526 shares of the biotechnology company's stock valued at $6,745,000 after buying an additional 2,112,382 shares in the last quarter. Northern Trust Corp increased its holdings in shares of OPKO Health by 4.7% in the 4th quarter. Northern Trust Corp now owns 3,697,774 shares of the biotechnology company's stock valued at $5,436,000 after purchasing an additional 164,847 shares during the period. Lazard Asset Management LLC raised its stake in shares of OPKO Health by 143.6% in the 4th quarter. Lazard Asset Management LLC now owns 2,548,667 shares of the biotechnology company's stock valued at $3,746,000 after acquiring an additional 1,502,342 shares in the last quarter. Finally, Two Sigma Investments LP grew its holdings in shares of OPKO Health by 136.1% during the 4th quarter. Two Sigma Investments LP now owns 1,647,567 shares of the biotechnology company's stock worth $2,422,000 after purchasing an additional 949,671 shares in the last quarter. Hedge funds and other institutional investors own 64.63% of the company's stock.

Insider Transactions at OPKO Health

In related news, CEO Phillip Md Et Al Frost purchased 675,000 shares of the business's stock in a transaction that occurred on Friday, August 8th. The shares were purchased at an average cost of $1.32 per share, with a total value of $891,000.00. Following the completion of the acquisition, the chief executive officer directly owned 214,676,448 shares of the company's stock, valued at approximately $283,372,911.36. The trade was a 0.32% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 49.69% of the company's stock.

Analyst Ratings Changes

Several research firms have issued reports on OPK. LADENBURG THALM/SH SH upgraded OPKO Health to a "strong-buy" rating in a research note on Tuesday, July 8th. Barrington Research reissued an "outperform" rating and set a $2.25 price objective on shares of OPKO Health in a report on Thursday, May 1st. Wall Street Zen downgraded OPKO Health from a "hold" rating to a "sell" rating in a research report on Monday, May 5th. Finally, JPMorgan Chase & Co. started coverage on OPKO Health in a research note on Friday, April 25th. They issued a "neutral" rating on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $2.75.

OPKO Health Stock Up 3.6%

OPK stock traded up $0.05 during trading on Monday, hitting $1.30. 1,752,015 shares of the company's stock traded hands, compared to its average volume of 3,899,425. The firm has a market capitalization of $1.03 billion, a P/E ratio of -5.18 and a beta of 1.19. The business has a fifty day simple moving average of $1.33 and a two-hundred day simple moving average of $1.47. OPKO Health, Inc. has a 1 year low of $1.11 and a 1 year high of $2.04. The company has a quick ratio of 3.02, a current ratio of 3.41 and a debt-to-equity ratio of 0.25.

OPKO Health (NASDAQ:OPK - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The biotechnology company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.07). OPKO Health had a negative return on equity of 13.17% and a negative net margin of 26.68%. The company had revenue of $156.80 million during the quarter, compared to analyst estimates of $165.74 million. During the same quarter in the prior year, the company posted ($0.01) earnings per share. The business's revenue was down 13.9% compared to the same quarter last year. Sell-side analysts anticipate that OPKO Health, Inc. will post -0.25 EPS for the current year.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.